Jon Rosenberg1, Allie Massaro1, James Siegler1, Stacey Sloate2, Matthew Mendlik1,3, Sherman Stein4, Joshua Levine1,5. 1. Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. 2. Wharton School of the University of Pennsylvania, Philadelphia, PA, USA. 3. Division of Palliative Care, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. 4. Died April 2019. 5. Department of Neurosurgery, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Abstract
BACKGROUND: Palliative care improves quality of life in patients with malignancy; however, it may be underutilized in patients with high-grade gliomas (HGGs). We examined the practices regarding palliative care consultation (PCC) in treating patients with HGGs in the neurological intensive care unit (NICU) of an academic medical center. METHODS: We conducted a retrospective cohort study of patients admitted to the NICU from 2011 to 2016 with a previously confirmed histopathological diagnosis of HGG. The primary outcome was the incidence of an inpatient PCC. We also evaluated the impact of PCC on patient care by examining its association with prespecified secondary outcomes of code status amendment to do not resuscitate (DNR), discharge disposition, 30-day mortality, and 30-day readmission rate, length of stay, and place of death. RESULTS: Ninety (36% female) patients with HGGs were identified. Palliative care consultation was obtained in 16 (18%) patients. Palliative care consultation was associated with a greater odds of code status amendment to DNR (odds ratio [OR]: 18.15, 95% confidence interval [CI]: 5.01-65.73), which remained significant after adjustment for confounders (OR: 27.20, 95% CI: 5.49-134.84), a greater odds of discharge to hospice (OR: 24.93, 95% CI: 6.48-95.88), and 30-day mortality (OR: 6.40, 95% CI: 1.96-20.94). CONCLUSION: In this retrospective study of patients with HGGs admitted to a university-based NICU, PCC was seen in a minority of the sample. Palliative care consultation was associated with code status change to DNR and hospice utilization. Further study is required to determine whether these findings are generalizable and whether interventions that increase PCC utilization are associated with improved quality of life and resource allocation for patients with HGGs.
BACKGROUND: Palliative care improves quality of life in patients with malignancy; however, it may be underutilized in patients with high-grade gliomas (HGGs). We examined the practices regarding palliative care consultation (PCC) in treating patients with HGGs in the neurological intensive care unit (NICU) of an academic medical center. METHODS: We conducted a retrospective cohort study of patients admitted to the NICU from 2011 to 2016 with a previously confirmed histopathological diagnosis of HGG. The primary outcome was the incidence of an inpatient PCC. We also evaluated the impact of PCC on patient care by examining its association with prespecified secondary outcomes of code status amendment to do not resuscitate (DNR), discharge disposition, 30-day mortality, and 30-day readmission rate, length of stay, and place of death. RESULTS: Ninety (36% female) patients with HGGs were identified. Palliative care consultation was obtained in 16 (18%) patients. Palliative care consultation was associated with a greater odds of code status amendment to DNR (odds ratio [OR]: 18.15, 95% confidence interval [CI]: 5.01-65.73), which remained significant after adjustment for confounders (OR: 27.20, 95% CI: 5.49-134.84), a greater odds of discharge to hospice (OR: 24.93, 95% CI: 6.48-95.88), and 30-day mortality (OR: 6.40, 95% CI: 1.96-20.94). CONCLUSION: In this retrospective study of patients with HGGs admitted to a university-based NICU, PCC was seen in a minority of the sample. Palliative care consultation was associated with code status change to DNR and hospice utilization. Further study is required to determine whether these findings are generalizable and whether interventions that increase PCC utilization are associated with improved quality of life and resource allocation for patients with HGGs.
Authors: Claire J Creutzfeldt; Ruth A Engelberg; Larry Healey; Chong Sherry Cheever; Kyra J Becker; Robert G Holloway; J Randall Curtis Journal: Crit Care Med Date: 2015-08 Impact factor: 7.598
Authors: J A F Koekkoek; L Dirven; J C Reijneveld; E M Sizoo; H R W Pasman; T J Postma; L Deliens; R Grant; S McNamara; W Grisold; E Medicus; G Stockhammer; S Oberndorfer; B Flechl; C Marosi; M J B Taphoorn; J J Heimans Journal: J Neurooncol Date: 2014-07-20 Impact factor: 4.130
Authors: Eli L Diamond; Geoffrey W Corner; Antonio De Rosa; William Breitbart; Allison J Applebaum Journal: J Neurooncol Date: 2014-05-30 Impact factor: 4.130
Authors: Christoph Ostgathe; Jan Gaertner; Maren Kotterba; Sebastian Klein; Gabriele Lindena; Friedemann Nauck; Lukas Radbruch; Raymond Voltz Journal: Support Care Cancer Date: 2009-09-08 Impact factor: 3.603